FDBusiness.com

New Clinical Trial Backs Arla Foods Ingredients’ Infant Immunity Ingredient

 Breaking News
  • Mars Wrigley Confectionery Names New Global President Mars, Incorporated has appointed Andrew Clarke, currently Chief Marketing & Customer Officer, to the role of Global President ‐ Mars Wrigley Confectionery. Andrew Clarke will assume his new role in September. He will be based at Mars Wrigley Confectionery’s global headquarters in Chicago, Illinois. Andrew Clarke. Since 2015 Andrew Clarke has been Chief Marketing & Customer Officer. [...]...
  • More Milk Needed to Cover Demand in 2030 – New Technologies Will Help Between now and 2030 worldwide demand growth for milk and milk products will be three times the level of current US milk production. This was one of the main findings of the latest publication, from the IFCN – the Dairy Research Network – discussed at the 19th IFCN Dairy Conference, held at Teagasc, Moorepark, Cork [...]...
  • Danone Early Life Nutrition Launches Category Overhaul Danone Early Life Nutrition is launching a category refresh that spans its leading baby food brands, Cow & Gate and Aptamil. Cow & Gate is launching fifteen new food recipes across the pouch, cereal, jar and tray product ranges, as well as a complete packaging re-brand across its entire formula milk and food portfolio. Starting from mid-June, [...]...
  • Speed Up Poultry Processing – 15,000 bph With Meyn Rising consumer demand for high-protein food and changing customer preferences have spurred the global market for poultry meat. In response to this growing demand, the market has been forced to increase production volumes. This results in longer production days and increased line speeds. Especially greenfield projects, but also existing plants demand the highest possible processing [...]...
  • Mondelēz International Invests $200 Million in Czech Biscuit Plant to Accelerate Growth in Europe Mondelēz International has invested $200 million since 2014 in its Czech Republic-based Opava biscuit manufacturing facility, which employs nearly 1,000 people and produces Power Brands like Oreo, belVita, Milka and Cadbury, for the European market. The investment builds on Opava’s proud heritage of more than a century as a biscuit-making centre and supports the company’s [...]...

New Clinical Trial Backs Arla Foods Ingredients’ Infant Immunity Ingredient

February 06
10:33 2014

Feeding babies with infant formula enriched with Arla Foods Ingredients’ Lacprodan® OPN-10 supports their immune development, according to the results of a new trial.

Lacprodan® OPN-10 is made from the whey protein osteopontin, a bioactive component associated with the maturation of the infant immune system. Osteopontin is found in high concentrations in human milk – about 138mg per litre – but in much lower concentrations in bovine milk (about 15mg per litre). This means infants fed regular formula have a limited intake compared with their breastfed counterparts.

Researchers from China’s Fundan University Hospital and the University of California at Davis conducted a double-blind randomised clinical trial in which Chinese infants aged between one and six months were fed either regular infant formula or infant formula supplemented with Lacprodan® OPN-10, with both groups compared with a reference group of breastfed babies.

The results showed that the babies who were given infant formula supplemented with Lacprodan® OPN-10 experienced a similar number of days of fever to those fed breast milk, and a reduced number of days of fever compared with a control group fed ordinary infant formula. The study also demonstrated that Lacprodan® OPN-10 is safe for use in infant formula.

The findings from the as-yet unpublished study were presented last week by Professor Bo Lönnerdal of the University of California at Davis during the 2nd International Conference on Nutrition & Growth, which took place from 30 January to 1 February 2014 in Barcelona, Spain.

Lotte Neergaard Jacobsen, Nutrition Scientist atArla Foods Ingredients, said: “The development of Lacprodan® OPN-10 is part of the quest to create infant formula that is more like breast milk. The results from this clinical study show that we have moved a step closer to achieving this. Osteopontin in the form of Lacprodan® OPN-10 could be a significant missing link in creating infant formula that can deliver a similar level of immune protection to that offered by mother’s milk.”

Experts at Arla Foods Ingredients have developed and patented the purification of osteopontin from cows’ milk and its application in infant and follow-on formulas, making it possible to create products with the same concentration of osteopontin as breast milk.

About Author

colin

colin

Related Articles



Food & Drink Business Conference & Exhibition 2016

Upcoming Events

  • June 17, 2018The Excellence of Italian Food and Wine (Bellavita Expo)
  • June 25, 2018Packaged., The 7th Global Summit
  • September 5, 2018Int'l Food Products and Processing Technologies Exhibition (WorldFood Istanbul)
  • September 15, 2018iba
AEC v1.0.4

find food jobs

The Magazine

F&D Business Preferred Suppliers

New Subscriber





Subscribe Here



Advertisements